This dataset contains SOMAscan targeted proteomics (1305 protein analytes) of serum of 54 patients with non-infectious uveitis (HLA-B27+ anterior uveitis, idiopathic intermediate uveitis, HLA-A29+ Birdshot chorioretinopathy, and 26 sex/age matched healthy controls without ocular inflammatory disease. The raw data files (adat files with relative fluorescent units for 1305 DNA aptamers for 80 samples), metadata, supplemental table 1-3, and R scripts (markdowns) as presented in: Kuiper et al. 2021 "A serum protein network predicts the early need for systemic immunomodulatory therapy in non-infectious uveitis" see preprint on MedRxiv

This dataset contains:

Supplemental Table 1-3 Supplemental table 1-3.xml xml file

Raw SOMAscan data MED-17-274.hybNorm.plateScale.medNorm.calibrate.20180425.adat adat file SOMAscan Quality Statement PDF file

R scripts with step-by-step analyses
"Figure_1.rmd" (see also "Figure_1.html") "Figure_2.rmd" (see also "Figure_2.html") "Figure_3.rmd" (see also "Figure_3.html") Metadata used in the R scripts (above) This includes data generated by Rieckmann et al., Nat Immunol. 2018 This includes data generated by Emilsson et al., Science 2018 This includes data generated by Selenter et al., Nucleic Acids Res. 2018

R studio, R version 4.0.3 (2020-10-10)

Objective biomarkers that can predict a severe disease course of autoimmune uveitis are lacking, and warranted for early identification of high-risk patients to improve visual outcome. The need for non-steroid immunomodulatory therapy (IMT) to control autoimmune uveitis is indicative of a more severe disease course. We used aptamer-based proteomics and a bioinformatic pipeline to uncover the serum protein network of 52 treatment-free patients and 26 healthy controls, and validation cohorts of 114 and 67 patients. Network-based analyses identified a highly co-expressed serum signature (n=85 proteins) whose concentration was consistently low in controls, but varied between cases. Patients that were positive for the signature at baseline showed a significantly increased risk for IMT during follow-up, independent of anatomical location of disease. In an independent cohort (n=114), we established robust risk categories and confirmed that patients with high levels of the signature at diagnosis had a significantly increased risk to start IMT during follow-up. Finally, we further validated the predictive association of the signature in a third cohort of 67 treatment-naive North-American patients. A serum protein signature was highly predictive for IMT in human autoimmune uveitis and may serve as an objective blood biomarker to aid in clinical-decision making.